BTIG lowered the firm's price target on Castle Biosciences to $40 from $50 and keeps a Buy rating on the shares. The company delivered a solid 10% revenue beat in Q1 on the back of robust volume growth in TissueCypher and its DecisionDx-Melanoma test, respectively, both ahead of the firm's forecast. Asymmetric upside remains in shares of Castle, with SCC having been priced out of the stock for some time now, the firm added.
